Compare Phillips 66 (PSX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs BIO-TECHNE Corp — how do they compare? Phillips 66 trades at $279.75 (market cap $108.38B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Phillips 66 is far larger — about 9.5× BIO-TECHNE Corp's market cap, and Phillips 66 pays the higher dividend (1.87%). Which is the better fit depends on your goals — on Pluang, investors hold Phillips 66 for 62 Days and BIO-TECHNE Corp for 63 Days on average.
| PSX | TECH | |
|---|---|---|
Market Cap | $108.38B | $11.37B |
Volume | 1,841,742 | 3,153,511 |
Sector | Energy | Health |
52-Week High | $281.60 | $72.61 |
52-Week Low | $126.76 | $43.31 |
Typical Hold Time | 62 Days | 63 Days |
Enterprise Value | $124.85B | $11.40B |
Dividend Yield | 1.87% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSX trades at $271.62, up 0.68% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $279. The stock has beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue declined to $132.38B in 2025, but net income improved to $4.40B, and 2026 projections show a rebound to $152.2B revenue and $7.1B net income. The company maintains a solid balance sheet with $72.58B in total assets and recently announced a $1.27 dividend for H2-2026.
The outlook for PSX is positive, supported by structural refining margins and AI-driven operational efficiencies. Investment opportunities include potential price appreciation toward the $279 consensus target and a sustainable dividend. Risks include exposure to volatile oil prices, regulatory changes such as potential diesel export bans, and execution challenges in maintaining profitability amid shifting energy demand.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
